Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Telaprevir preparation method

A technology of telaprevir and compounds, which is applied in the field of preparation of telaprevir, can solve the problem of high cost, achieve the effects of improving synthesis yield, mild reaction conditions, and cheap and easy-to-obtain raw materials

Inactive Publication Date: 2014-02-05
HYBIO PHARMA
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The solid-phase method is relatively expensive due to the need for excessive feeding

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Telaprevir preparation method
  • Telaprevir preparation method
  • Telaprevir preparation method

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0029] The embodiment of the present invention discloses a preparation method of telaprevir. Those skilled in the art can refer to the content of this article to appropriately improve the process parameters to achieve. In particular, it should be pointed out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method of the present invention has been described through preferred embodiments, and relevant personnel can obviously make changes or appropriate changes and combinations to the method described herein without departing from the content, spirit and scope of the present invention to realize and apply the technology of the present invention .

[0030] For realizing the purpose of the present invention, the present invention adopts following technical scheme:

[0031] A preparation method of telaprevir, comprising:

[0032] Step 1: Condensation of 2-carboxypyrazi...

Embodiment 1

[0067] Embodiment 1: the preparation of compound 3

[0068] Dissolve pyrazine 2-carboxylate (2.48g, 20mmol) and HONb (3.942g, 22mmol) in 50mL THF, add DCC (4.539g, 22mmol) under ice-bath conditions, keep stirring in the ice-bath for 1h, remove the ice-bath, Stir at room temperature for 2h, filter, and the filtrate is set aside.

[0069] L-cyclohexylglycine (3.144g, 20mmol) and Na 2 CO 3 (2.12g, 20mmol) was dissolved in 100mL H 2 O, under ice-bath conditions, the above filtrate was added dropwise while stirring, and after the dropwise addition was completed, the reaction was carried out at room temperature for 2 h. Stop the reaction, concentrate THF in vacuo, add 50mL EA, adjust the pH to 3 with saturated citric acid, stir for 0.5h, separate the organic phase, wash with saturated brine three times, and dry over anhydrous sodium sulfate. Concentrated in vacuo, the obtained oil was recrystallized with ether to obtain 4.27g of white powdery solid, yield: 81%, MS: 264(M+1), 286...

Embodiment 2

[0070] Embodiment 2: the preparation of compound 5

[0071] Compound 3 (2.63g, 10mmol) and HONb (1.97g, 11mmol) were dissolved in 30mL THF, DCC (2.269g, 11mmol) was added under ice-bath conditions, kept stirring in the ice bath for 1h, removed the ice bath, and stirred at room temperature 2h, filtered, and the filtrate was set aside.

[0072] L--tertiary leucine (1.311g, 10mmol) and NaHCO 3 (1.768g, 20mmol) was dissolved in 50mL H 2 O, under ice-bath conditions, the above filtrate was added dropwise while stirring, and after the dropwise addition was completed, the reaction was carried out at room temperature for 3 h. Stop the reaction, concentrate THF in vacuum, extract twice with petroleum ether, add 25mL EA to the water phase, adjust the pH to 3 with saturated citric acid, stir for 0.5h, separate the organic phase, wash with saturated brine three times, and dry over anhydrous sodium sulfate. Concentrated in vacuo, the resulting foamy solid was recrystallized with PE-EA t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the pharmaceutical chemistry field, and especially relates to a telaprevir preparation method. The preparation method comprises the following steps: reacting an initial raw material 2-pyrazinecarboxylic acid with L-cyclohexylglycine by adopting a smallest protection strategy, reacting with L-tert-leucine, reacting with (1S,3aR,6aS)-octahydro-cyclopenta[c]pyrrole-1-carboxylic acid to obtain a compound 7, wherein the synthesis step is shortened; and condensing the compound 7, a compound 8 and cyclopropane to obtain telaprevir. The preparation method has the advantages of avoiding of the adoption of a low-yield oxidation reaction in the synthesis, synthesis yield improvement, cheap and easily available raw materials, mild reaction conditions, and suitableness for the large scale production.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, in particular to a preparation method of telaprevir. Background technique [0002] Telaprevir (VX-950) is a new drug developed by Vertex Pharmaceuticals of the United States for the treatment of hepatitis C. It was approved by the FDA on May 23, 2011, and its trade name is Incivek. The drug is an oral tablet, which is a reversible protease inhibitor, used in combination with peginterferon-alpha and ribavirin, can effectively inhibit the replication of HVC virus, and is used for the treatment of chronic hepatitis C . [0003] Telaprevir English chemical name: (1S,3aR,6aS)-N-[1(S)-[2-(cyclopropyl-amino)ox alyl]butyl]-2-[N-(pyrazin-2-ylcarbonyl) -L-cyclohexylglycyl-3-methyl-L-valyl]perh ydrocyclopenta[c]pyrrole-1-carboxamide; Molecular formula: C 36 h 53 N 7 o 6 ; Relative molecular mass: 679.85; CAS registration number: 402957-28-2, the structural formula is as follows: [0004] [0005...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06C07K1/06C07K1/02
CPCY02P20/55
Inventor 陈友金潘俊锋马亚平袁建成
Owner HYBIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com